BlackRock Leads Sema4’s $121M Series C

Patient-centered health intelligence company Sema4 saw its post-money valuation go above $1 billion after closing an oversubscribed $121 million Series C financing round, the company announced Wednesday.

Subscribe to the Crunchbase Daily

Stamford, Connecticut-based Sema4 is a 2017 Mount Sinai Health System spinoff using its Centrellis health intelligence platform to improve patient outcomes by providing science-driven diagnosis, treatment and prevention in the initial areas of reproductive health and oncology.

BlackRock led the oversubscribed round that also included new investors Deerfield Management Company and Moore Strategic Ventures, the company said in a written statement. The Series C comes less than a year after Sema4 raised its Series B—its first round of external funding at just over $120 million from Blackstone, Section 32, Oak HC/FT, Decheng and Connecticut Innovations, all companies that also participated in its Series C, according to the company.

“This investment is exciting for the significant financial resources it provides Sema4 for our continued rapid growth and accelerated investment, and also for the world-renowned partners it brings to our team,” said Eric Schadt, founder and CEO of Sema4, in a written statement. “

As part of the investment, Deerfield Partner Andrew Elbardissi, M.D., joined Sema4’s board of directors.

In April, Sema4 launched COVID-19 testing efforts for high-risk individuals and medical personnel across Connecticut and New York. In June, FierceBiotech reported that the company expanded its relationship with the State of Connecticut to provide COVID-19 testing to residents, as well as state employees and first responders.

Illustration: Li-Anne Dias